A clinical trial to assess the effectiveness of a combination immunotherapy versus active surveillance for treated hepatocellular patients who are at high risk of recurrence.

Study in progress
This research study is no longer accepting participants. The following details are for information only.

About this study

The purpose of this study is to compare the effects, good or bad, of combination immunotherapy (atezolizumab plus bevacizumab) versus observation (not receiving any treatment) on participants with completely resected or ablated hepatocellular cancer (HCC) who are at high risk for disease recurrence.

In this study, patients will receive either atezolizumab plus bevacizumab or no treatment.

Anticipated enrolment close date: 31 December 2022

Who can take part

Inclusion criteria

  • First diagnosis of HCC who have undergone a curative resection/ablation (RFA or MWA only)
  • High risk of HCC recurrence after resection/ablation

Exclusion criteria

  • Prior or recurrent history of HCC
  • Have received other treatment for HCC before surgery/ablation
  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC

What's involved

Weekly immunotherapy infusions over three weeks

Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

The RMH Clinical Trials Centre
Clinical Trials Centre

The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.

The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.